Document is current
Any future updates will be listed below
-
Authors
Yu, Langtian Abigail
Ning, Fangling
Wang, Xiaole
Peng, Peijian
Zhang, Hongyu
Huang, Guofu
Sun, Yuping
Zhou, Zhili
Li, JunJie
Hsieh, Chih-Yi
Luk, Alvin
Zhang, Vivien
Sun, David W
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05892718 at ClinicalTrials.govnct06771622 at ClinicalTrials.govDocuments that mention this clinical trial
1331 HCB101, a next-generation Fc-engineered anti-CD47 SIRPα fusion protein, demonstrates favorable safety and early antitumor activity in advanced cancers
https://doi.org/10.1136/jitc-2025-sitc2025.1331
1332 Phase Ib/IIa study of HCB101 combined with standard therapies demonstrates manageable safety and dose-dependent antitumor activity in immunologically cold advanced solid tumors
https://doi.org/10.1136/jitc-2025-sitc2025.1332
nct06771622 at ClinicalTrials.govDocuments that mention this clinical trial
1332 Phase Ib/IIa study of HCB101 combined with standard therapies demonstrates manageable safety and dose-dependent antitumor activity in immunologically cold advanced solid tumors
https://doi.org/10.1136/jitc-2025-sitc2025.1332
Documents that mention this clinical trial
1332 Phase Ib/IIa study of HCB101 combined with standard therapies demonstrates manageable safety and dose-dependent antitumor activity in immunologically cold advanced solid tumors
https://doi.org/10.1136/jitc-2025-sitc2025.1332
- License Information
